Analysts Offer Insights on Healthcare Companies: Verastem (NASDAQ: VSTM), Evoke Pharma (NASDAQ: EVOK) and Aduro BioTech (NASDAQ: ADRO)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verastem (NASDAQ: VSTM), Evoke Pharma (NASDAQ: EVOK) and Aduro BioTech (NASDAQ: ADRO) with bullish sentiments.

Verastem (NASDAQ: VSTM)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Verastem (NASDAQ: VSTM) today and set a price target of $10. The company’s shares closed yesterday at $4.39.

Ramakanth said:

“Olga Smolentseva, Ph.D. – (646-975-6966) / osmolentseva@hcwresearch.com Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5.”

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 4.3% and a 36.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.

Currently, the analyst consensus on Verastem is Strong Buy and the average price target is $13, representing a 196.1% upside.

In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $17 price target.

See today’s analyst top recommended stocks >>

Evoke Pharma (NASDAQ: EVOK)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Evoke Pharma (NASDAQ: EVOK) today and set a price target of $9. The company’s shares closed yesterday at $2.45.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 35.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Evoke Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $7.

Aduro BioTech (NASDAQ: ADRO)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aduro BioTech (NASDAQ: ADRO), with a price target of $9.50. The company’s shares closed yesterday at $7.25.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.6% and a 33.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Aduro BioTech is Strong Buy and the average price target is $16.88, representing a 132.8% upside.

In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $13 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts